# Lymphotoxin- $\alpha$ - and Lymphotoxin- $\beta$ -Deficient Mice Differ in Susceptibility to Scrapie: Evidence against Dendritic Cell Involvement in Neuroinvasion†

Michael B. A. Oldstone,<sup>1</sup>\* Richard Race,<sup>2</sup> Diane Thomas,<sup>1</sup> Hanna Lewicki,<sup>1</sup> Dirk Homann,<sup>1</sup> Sara Smelt,<sup>1</sup> Andreas Holz,<sup>1</sup> Pandelakis Koni,<sup>3</sup> David Lo,<sup>4</sup> Bruce Chesebro,<sup>2</sup> and Richard Flavell<sup>3</sup>

*Division of Virology, Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California 92037*<sup>1</sup> *; Laboratory of*

*Persistent Viral Diseases, Rocky Mountain Laboratories, Hamilton, Montana 59840*<sup>2</sup> *; Howard Hughes Medical Institute,*

*Section of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06520*<sup>3</sup> *;*

*and Digital Gene Technologies, Inc., La Jolla, California 92037*<sup>4</sup>

Received 6 November 2001/Accepted 28 January 2002

**Transmissible spongiform encephalopathy or prion diseases are fatal neurodegenerative disorders of humans and animals often initiated by oral intake of an infectious agent. Current evidence suggests that infection occurs initially in the lymphoid tissues and subsequently in the central nervous system (CNS). The identity of infected lymphoid cells remains controversial, but recent studies point to the involvement of both follicular** dendritic cells (FDC) and CD11c<sup>+</sup> lymphoid dendritic cells. FDC generation and maintenance in germinal **centers is dependent on lymphotoxin alpha (LT-α) and LT-β signaling components. We report here that by the oral route, LT-** $\alpha$  **–/– mice developed scrapie while LT-β –/– mice did not. Furthermore, LT-** $\alpha$  **–/– mice had a higher incidence and shorter incubation period for developing disease following inoculation than did LT-**  $-/-$  mice. Transplantation of lymphoid tissues from LT- $\beta$   $-/-$  mice, which have cervical and mesenteric lymph nodes, into LT- $\alpha$  –/– mice, which do not, did not alter the incidence of CNS scrapie. In other studies, **a virus that is tropic for and alters functions of CD11c cells did not alter the kinetics of neuroinvasion of** scrapie. Our results suggest that neither FDC nor CD11c<sup>+</sup> cells are essential for neuroinvasion after high doses of RML scrapie. Further, it is possible that an as yet unidentified cell found more abundantly in  $LT\text{-}\alpha$  $-/-$  than in LT- $\beta$   $-/-$  mice may assist in the amplification of scrapie infection in the periphery and favor **susceptibility to CNS disease following peripheral routes of infection.**

Transmissible spongiform encephalopathy (TSE), scrapie, or prion diseases are fatal neurodegenerative disorders (12, 30, 40). In many natural and experimental situations transmission occurs by ingestion of infectious material. In addition to transmission by ingestion, TSE disease can be transmitted by inoculation or transplantation of infected tissues or extracts, for example in iatrogenic human TSE or in experimental animal TSE models. Typically, TSE infection of humans and animals results in conversion of normal prion protein (PrPc) to the disease-associated protease-resistant form, PrPsc. Follicular dendritic cells (FDCs) in germinal centers of lymphoid organs have been implicated as initial sites of accumulation of PrP<sup>sc</sup> and infectivity (see reviews [12, 30, 40]). The subsequent passage of scrapie infection from peripheral lymphoid sites to the central nervous system (CNS) occurs mostly via neuronal transport (5, 18, 31, 34). This was shown in a variety of experiments using normal animals infected with scrapie in which the agent was tracked in nerves or failed to reach the CNS when nerves were cut. In other experiments neuroinvasion was seen after oral or intraperitoneal (i.p.) infection of mice in which PrP was expressed only in neurons using the neuron-specific enolase promoter, strongly suggesting that transmission is restricted by neurons (31). This conclusion was further supported as splenectomy did not influence the kinetics of migration and incidence of TSE disease, suggesting that FDCs did not play a role.

FDCs  $(8, 9, 17, 23, 25-27)$  and in recent reports CD11c<sup>+</sup> dendritic cells (3) appear to play an important role in the peripheral amplification of infectivity prior to neuroinvasion. In the present study we evaluated the role of FDCs in oral and i.p. infection of mice by scrapie agent. Since FDC generation and maintenance in germinal centers is dependent on lymphotoxin alpha (LT- $\alpha$ ) and LT- $\beta$  signaling components (2, 4, 13, 15, 20, 39), we infected LT- $\alpha$  and LT- $\beta$  knockout mice with scrapie and studied the accumulation of PrP<sup>sc</sup> in their spleens and brains, the presence of infectious scrapie in their CNS, and the development of progressive neurodegenerative disease. We also investigated whether  $CD11c<sup>+</sup>$  dendritic cells played an essential role in neuroinvasion of scrapie by using lymphocytic choriomeningitis virus (LCMV) Clone 13, which specifically infects and aborts the function of such  $CD11c^+$  cells (21, 35). Interestingly,  $LT-\alpha^{-/-}$  mice were found to have a higher disease incidence and shorter incubation period than  $LT-\beta^{-/-}$ mice despite similar depletion of FDCs. Our results supported the conclusion that neither FDCs nor  $CD11c<sup>+</sup>$  cells are absolutely required for neuroinvasion in TSE disease caused by the RML strain of mouse scrapie. Further, our findings indicate that in addition to FDCs and  $CD11c<sup>+</sup>$  cells, a unique cell(s) found more abundantly in  $LT-\alpha^{-/-}$  than in  $LT-\beta^{-/-}$  mice

<sup>\*</sup> Corresponding author. Mailing address: Department of Neuropharmacology (IMM-6), The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037. Phone: (858) 784-8054. Fax: (858) 784-9981. E-mail: mbaobo@scripps.edu.

<sup>†</sup> Publication no. 13841-NP from the Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037.

likely assists in the amplification of scrapie infection in the periphery and favors susceptibility for CNS disease following peripheral routes of infection.

### **MATERIALS AND METHODS**

**Mice.** LT- $B^{-/-}$  mice and LT- $B^{+/+}$  mice were described previously (20). LT- $\alpha$ <sup>-/-</sup> mice were derived originally by David Chaplin (Washington University, St. Louis, Mo.) (14).  $\text{Re} \cdot \text{Re}^{-/-}$  mice were made as described previously (10). Genotyping confirmed their LT- $\alpha$  and LT- $\beta$  status (10, 14, 20). All mice were on a mixed background of C57Bl/6 and 129/Sv (B6  $\times$  129). CD4, CD8, β2-microglobulin, and major histocompatibility complex (MHC) class II gene-disrupted mice on B6 background were derived and characterized as reported. Breeding and maintenance of these mice and of C57Bl/6 and BALB/cjd mice were performed under specific-pathogen-free conditions at the Rodent Breeding Colony, The Scripps Research Institute (La Jolla, Calif.).

**Infectious agents and infection of mice.** Mice were inoculated by oral, i.p., or intracerebral (i.c.) routes with various doses of the RML strain of mouse scrapie (31). i.p. inoculation volume was 100  $\lambda$ , and i.c. inoculation volume was 30  $\lambda$ . Oral infection was in a volume of 200  $\lambda$  administered via a small-diameter flexible polypropylene catheter inserted over the base of the tongue about 1 to 2 cm into the esophagus (31). Quantitation of infectious scrapie in brains was accomplished by i.c. injection of serial 10-fold dilutions of a 10% brain homogenate into B6 mice (four mice/dilution). The LCMV ARM 53b strain is a triple plaquepurified isolate of ARM CA 1371 and was passaged in baby hamster kidney (BHK) cells (35). Cl 13 is a triple plaque-purified variant of ARM 53b derived from spleen cells of an adult BALB/WEHI mouse persistently infected since birth with ARM 53b (1, 33). Either virus ( $2 \times 10^6$  PFU) was inoculated intravenously (i.v.) into B6  $\times$  129, B6, or BALB/cdj mice (35). Inoculated mice were sacrificed when moribund, or when healthy at 11 to 12 months postadministration of mouse scrapie.

**RNase protection assay.** The RNase protection assay was performed using probe sets from Pharmingen (La Jolla, Calif.) where 20 µg of total RNA obtained from brains of control,  $LT$ - $\alpha$ <sup>-/-</sup>,  $LT$ - $\beta$ <sup>-/-</sup>, or RelB<sup>-/-</sup> mice were hybridized to  $32P$ -labeled riboprobes from various sets (16). After digestion with RNase, the material was separated on a sequencing gel, and the intensity of the protected RNA fragments was quantified using an ImageQuant system with appropriate software (Molecular Dynamics). Each transcript level was normalized to the ubiquitous housekeeping L32 RNA.

**PrPsc purification.** Twenty-percent tissue homogenates were made in a solution containing 0.01 M Tris-HCl (pH 7.4) and 0.005 M MgCl using disposable Konex microcentrifuge tubes and matched pestles. Homogenates were sonicated for 2 min, and then DNase was added (1.0 mg/g of starting tissue) and the suspension incubated for 1 h at 37°C in a swirling water bath. An equal volume of 20% sarcosyl in 0.01 M Tris-HCl (pH 7.4) was added, and the suspension was vortexed and then incubated at room temperature for 1 h. Suspensions were centrifuged at  $10,000 \times g$ , 30 min, 10°C, and the resulting supernatant was centrifuged at 215,000  $\times$  g for 2 h at 10°C. The resulting pellet was resuspended by sonication in sterile water (1.0 ml/200 mg of starting tissue). Twenty-five micrograms of proteinase K/200 mg of starting tissue was added, and the suspension was incubated at 37°C in a swirling water bath for 30 min. Proteinase K activity was terminated by the addition of  $25 \mu l$  of 0.1 M phenylmethylsulfonyl fluoride/ml of suspension followed by cooling on ice for 15 min. Suspensions were then centrifuged at  $215,000 \times g$  for 1 h at 10°C. Pellets were resuspended in sample buffer by sonication, boiled 5 min, and then frozen until needed. Immunoblotting as described previously (31) was used to detect PrPsc.

## **RESULTS**

Comparison of scrapie infection by various routes in  $LT-\alpha$ **and LT-** $\beta$  **gene knockout mice.** Injection of  $10^7$  50% lethal doses  $(LD_{50})$  of the RML strain of murine scrapie directly into the brains of control (LT- $\alpha^{+/+}$  and LT- $\beta^{+/+}$ ), LT- $\alpha^{-/-}$ , or LT- $\beta$ <sup>-/-</sup> mice led to 100% mortality in all groups studied (four to six mice/group) with either death or severe morbidity requiring sacrifice at nearly equivalent times postinoculation (Fig. 1; Table 1). As expected, brains harvested from representative mice of each group expressed PrP<sup>sc</sup> (Table 1; Fig. 2) and the classic histologic picture of neuronal degeneration, spongiosis, and astrocytosis. In preliminary studies normal con-



FIG. 1. LT- $\alpha^{-/-}$  mice and LT- $\beta^{-/-}$  mice differ in susceptibility to RML mouse scrapie administered orally or i.p. Control  $LT-\alpha^{-1}$ <sup>-</sup> mice and  $LT$ - $\beta$ <sup>-/-</sup> mice were 8 weeks old when inoculated. For i.c. inoculation, four control mice, six LT- $\alpha^{-/-}$  mice, and six LT- $\beta^{-/-}$  mice were used. For oral inoculation, 10 control mice, 10 LT- $\alpha^{-/-}$  mice, and 10  $LT$ - $\beta$ <sup>-/-</sup> mice were injected. Similar results occurred after a repeat experiment with six  $LT-\alpha^{-/-}$  mice and six  $LT-\beta^{-/-}$  mice. For i.p. inoculation, 10 control mice, 10 LT- $\alpha^{-/-}$  mice, and 16 LT- $\beta^{-/-}$  mice were employed.

trol mice receiving  $10^{5.5}$  LD<sub>50</sub> orally did not develop TSE by 380 days, whereas all given  $10^7$  LD<sub>50</sub> orally died before 290 days (five mice/group). Therefore, for all subsequent experiments  $10^7$  LD<sub>50</sub> of mouse scrapie was administered orally or i.p. When control mice (10 per group) received murine scrapie orally or by the i.p. route with  $10^7$  LD<sub>50</sub> of RML scrapie, all died by day  $288 \pm 8$  (mean  $\pm 1$  standard deviation: oral route) or day 189  $\pm$  5 (i.p. route), expressed PrP<sup>sc</sup>, and manifested abnormal histopathology in their brains (Table 1). To the contrary and as anticipated, none of the  $PrP^{-/-}$  mice inoculated i.c. became clinically ill over a 375-day observation period; these mice did not express PrPsc, nor were histopathologic abnormalities evident in brain tissue.

None of the 10 LT- $\beta^{-/-}$  mice receiving 10<sup>7</sup> LD<sub>50</sub> of RML scrapie by the oral route died over a 314- to a 365-day obser-

| Mouse<br>genotype                | Route of scrapie<br>inoculation <sup>b</sup> | No. of mice developing<br>disease <sup>c</sup> | Days (d) to terminal disease or sacrifice <sup>d</sup>              | Detection of PrPsc<br>in $CNSc$ |  |  |
|----------------------------------|--|--|---|---------------------------------|--|--|
| $PrP^{-/-}$<br>i.c.              |  | 0/3  | 375   | 0/3                             |  |  |
| $\mathrm{Pr}\mathrm{P}^{+/+}$    | i.c.   | 6/6  | $180 \pm 4^e$   | 4/4                             |  |  |
| $LT\textrm{-}\alpha^{-/-}$       | i.c.   | 4/4  | $189 \pm 5^e$   | 4/4                             |  |  |
| $LT-\beta^{-/-}$                 | i.c.   | 4/4  | $178 \pm 4^e$   | 4/4                             |  |  |
| $ReIB^{-/-}$                     | i.c.   | 2/2  | $179 \pm 4^e$   | 2/2                             |  |  |
| $LT^{+/+}$                       | Oral   | 10/10  | $288 \pm 8^{e}$   | 7/7                             |  |  |
| $LT\textrm{-}\alpha^{-/-}$       | Oral   | 5/5  | d275, d298, d278, d291, d285  | 5/5                             |  |  |
|                                  |  | 0/5  | d345, d345, d360, d365, d365  | 0/5                             |  |  |
| $LT-\beta^{-/-}$                 | Oral   | 0/10   | d314, d314, d349, d349, d349, d349,<br>d360, d360, d365, d365       | 0/10                            |  |  |
| $ReIB^{+/+}$                     | Oral   | 2/2  | d291, d296  | 2/2                             |  |  |
| $ReIB^{-/-}$                     | Oral   | 0/3  | d365, d365, d365  | 0/3                             |  |  |
| $\mathop{\rm LT}\nolimits^{+/+}$ | i.p.   | 10/10  | $189 \pm 5^e$   | 4/4                             |  |  |
| $LT-\alpha^{-/-}$                | 1.p.   | 9/10   | d211, d239, d239, d220, d220, d220,<br>8/8<br>d247, d242, d242      |                                 |  |  |
|                                  |  | 0/1  | d348  | 1/1                             |  |  |
| $LT-\beta^{-/-}$                 | i.p.   | 5/5  | d293, d293, d291, d299, d298  | 3/3                             |  |  |
|                                  |  | 0/11   | d355, d355, d355, d355, d355, d360,<br>d360, d368, d368, d368, d368 | 0/9                             |  |  |

TABLE 1. Scrapie disease in LT- $\alpha^{-/-}$ , LT- $\beta^{-/-}$ , RelB<sup>-/-</sup>, and control mice<sup>*a*</sup>

<sup>*a*</sup> RML mouse scrapie (10<sup>7</sup> LD<sub>50</sub>) was given to 8-week-old C57BL/6  $\times$  129 mice. *b* i.c., intracerebral; i.p., intraperitoneal.

*<sup>c</sup>* Number of mice positive/total mice in a group.

*d* Day mice were moribund or died, or they were sacrificed when clinically free of scrapie disease. *e* Mean + 1 standard deviation.

vation period (Fig. 1; Table 1). Neither infectivity nor PrPsc was found in the brain of any of these orally inoculated LT-  $\beta^{-/-}$  mice (Fig. 2; Table 1). We reported that tumor necrosis factor (TNF) mRNA was markedly increased in the brains of mice undergoing scrapie-induced disease, with the level of these transcripts paralleling the severity of disease (11). Accordingly, brains of  $LT-\beta^{-/-}$  mice inoculated orally failed to overexpress either tumor necrosis factor alpha (TNF- $\alpha$ ) or TNF- $\beta$  mRNA (Fig. 3).

 $LT$ - $\alpha$ <sup>-/-</sup> mice inoculated orally segregated into two groups. Fifty percent developed clinical scrapie and were sacrificed by



Route of Inoculation

FIG. 2. Lack of PrP<sup>sc</sup> expression in brains of  $LT- $\beta^{-/-}$  mice inocu$ lated orally or i.p. with  $10^7$  LD<sub>50</sub> of RML mouse scrapie (see Table 1). Lanes 2 and 3 represent two  $LT$ - $\alpha$ <sup>-/-</sup> mice inoculated orally, and lanes 7 and 8 show results for two other  $LT-\alpha^{-/-}$  mice inoculated i.p. All illustrate the expression of  $PrP^{sc}$ . As displayed in lanes 4 and 5, no expression of PrP<sup>sc</sup> was evident in brains of  $LT-B^{-/-}$  mice after oral inoculation or after i.p. inoculation, as in lanes 9 and 10. Similar results were found with additional samples from  $LT-\alpha^{-/-}$  and  $LT-\beta^{-/-}$  mice as recorded in Table 1.

day 285  $\pm$  4, whereas the other 50% failed to show clinical disease by day 345 to 360 (Fig. 1; Table 1). As anticipated, those  $LT$ - $\alpha$ <sup>-/-</sup> mice developing clinical scrapie expressed both PrP<sup>sc</sup> (Fig. 2) and TNF mRNA (Fig. 3) in their brains. Furthermore, infectivity was found in the brains of these mice as detected by inoculation into normal recipients.

The differences between  $LT$ - $\beta$ <sup>-/-</sup> and  $LT$ - $\alpha$ <sup>-/-</sup> mice as regards susceptibility to scrapie infection were further confirmed when these mice were given scrapie by the i.p. route. In this instance, 9 of 10 inoculated  $LT-\alpha^{-/-}$  mice developed clinical scrapie and had PrP<sup>sc</sup> in their brains. The onset of disease was significantly ( $P < 0.01$ ) slower (230  $\pm$  5 days) in these LT- $\alpha$ <sup>-/-</sup> mice than in age- and sex-matched LT- $\alpha^{+/+}$  mice (day 189  $\pm$ 5) given the same dose of scrapie. The lone clinically healthy  $LT$ - $\alpha$ <sup>-/-</sup> mouse was sacrificed at 348 days after scrapie inoculation, and its brain contained PrP<sup>sc</sup> and infectious scrapie. In contrast to LT- $\alpha^{-/-}$  mice, only 5 of 16 (31%) LT- $\beta^{-/-}$  mice developed TSE disease after i.p. inoculation of scrapie and had PrP<sup>sc</sup> in their brains, whereas the remaining 11 of 16 (69%) mice did not (Fig. 1 and 2; Table 1). Brains from the latter group also failed to express TNF mRNA (Fig. 3). The mean time interval required for disease to develop was shorter in LT- $\alpha^{-/-}$  mice (day 230  $\pm$  5) than in the LT- $\beta^{-/-}$  group (day  $295 \pm 2$ ) ( $P < 0.001$ ). Intracerebral inoculation of 10% brain homogenates from five of the i.p.-inoculated clinically healthy,  $PrP^{sc}$  nil LT- $\beta^{-/-}$  mice into control mice has not led to scrapie over a 345-day observation period.

**Enhanced susceptibility of LT-** $\alpha^{-/-}$  **mice over LT-** $\beta^{-/-}$ mice is not due to differences in FDC populations of  $LT-\alpha^{-/-}$ or  $LT$ - $\beta$ <sup>-/-</sup> mice or the presence of cervical and mesenteric **lymph nodes or thymic tissues in**  $LT$ **-** $\beta$ **<sup>-/-</sup> mice.** The enhanced susceptibility of  $LT-\alpha^{-/-}$  mice over that of  $LT-\beta^{-/-}$  mice to both oral and i.p. administration of scrapie, coupled with the longer interval between infection and clinical disease in LT-



FIG. 3. Transcripts of TNF- $\alpha$  or - $\beta$  mRNA appear in brains of LT- $\alpha^{-/-}$  mice receiving 10<sup>7</sup> LD<sub>50</sub> of RML scrapie orally or i.p. These mice develop clinical disease, display histopathologic lesions, and express  $Pr^{psc}$  associated with scrapie disease. In contrast,  $LT^{-\beta^{-/-}}$  mice after oral or i.p. inoculation, or RelB-/- mice after oral administration of scrapie, fail to develop scrapie disease or show transcripts of TNF- $\alpha$  or - $\beta$  mRNA in their brains. Results were similar for three additional  $LT$ - $\beta$ <sup>-/-</sup> mice and one ReIB<sup>-/-</sup> mouse studied (data not shown). Each transcript level was normalized to the ubiquitous housekeeping L32 RNA.

 $\beta^{-/-}$  mice (day 295  $\pm$  2) compared to LT- $\alpha^{-/-}$  mice (day 230)  $\pm$  5), led us to evaluate both the numbers of FDCs in LT- $\beta$ <sup>-/-</sup> mice versus  $LT-\alpha^{-/-}$  mice and possible immunologic protection by cervical and mesenteric lymph nodes or thymic tissues in  $LT-\beta^{-/-}$  mice. FDCs are known cells in lymphoid organs implicated in the replication of scrapie infectivity (8, 9, 17, 23, 25–27). Examination of three spleens randomly chosen from both  $LT-\alpha^{-/-}$  and  $LT-\beta^{-/-}$  mice, as expected from observations of others (2, 10, 13, 14, 20), showed the absence of FDCs as determined by the use of FDC-M2 antibodies on cryomicrotome sections. Hence, by the assays used, the susceptibility of  $LT-\alpha^{-/-}$  mice to peripheral routes of scrapie infection was not attributable to residual or extra FDCs.

 $LT-\beta$ <sup>-/-</sup> mice are reported to have cervical and mesenteric lymph nodes, whereas  $LT-\alpha^{-/-}$  mice do not (2, 14, 20, 22). However, one report (4) concluded that a subset of  $LT-\alpha^{-/-}$ mice have abnormal lymphoid-like structures in their mesenteric fat, perhaps accounting for the biphasic response we noted (Fig. 1). To ascertain whether lymphoid cells might provide resistance against peripheral TSE infection for LT-  $\beta^{-/-}$  mice, we removed their cervical and mesenteric lymph nodes and initially examined such tissues for FDCs using FDC-M2 antibodies. As anticipated, no FDCs were observed. In a separate series of studies we adoptively transferred cervical and mesenteric lymph node cells i.p. or implanted the tissue with and without thymic tissue from  $LT-\beta^{-/-}$  mice (four mice/ group) under the renal capsule (38) of  $LT-\alpha^{-/-}$  mice. One week after transplantation,  $LT-\alpha^{-/-}$  mice reconstituted with

LT- $\beta$  lymphoid cells were challenged with 10<sup>7</sup> LD<sub>50</sub> of RML scrapie i.p. No difference was seen in the time required for developing scrapie in LT- $\alpha^{-/-}$  mice reconstituted with LT- $\beta$ lymphoid cells (days 230 to 250) compared to regular  $LT-\alpha^{-/-}$ mice. These results indicated it is likely that the cervical and mesenteric lymph nodes and thymic tissue from  $LT-\beta^{-/-}$  mice had no protective effect against TSE disease.

**RelB/ mice fail to develop TSE after oral administration** of mouse scrapie. RelB<sup>-/-</sup> mice, like LT- $\alpha^{-/-}$  and LT- $\beta^{-/-}$ mice, lack FDCs and exhibit disordered splenic architecture (10). However, unlike  $LT-\alpha^{-/-}$  or  $LT-\beta^{-/-}$  mice, RelB<sup>-/-</sup> mice also have abnormal thymic medullary cells.  $ReIB^{-/-}$  mice given scrapie orally failed to develop disease and did not express PrP<sup>sc</sup> (Table 1) or TNF mRNA in their brains (Fig. 3) over a 1-year observation time (three of three mice). In contrast, i.c. inoculation of scrapie into  $\text{Re} \text{IB}^{-/-}$  mice resulted in both a clinical and a histopathologic picture of scrapie disease as well as expression of PrP<sup>sc</sup> in brain tissues. Therefore, RelB<sup>-/-</sup> mice, like LT- $\beta$ <sup>-/-</sup> mice, are resistant to orally administered RML scrapie. By contrast, 200 days after oral inoculation of scrapie into  $\text{RelB}^{+/-}$  or  $\text{RelB}^{+/+}$  mice (two to three mice per group), clinical and histopathologic evidence of scrapie as well as expression of PrP<sup>sc</sup> in the CNS were clear.

Dysfunction of splenic DEC205<sup>+</sup> and CD11c<sup>+</sup> lymphoid **dendritic cells does not alter the kinetics for development of TSE after peripheral administration of mouse scrapie.** After i.v. administration of  $2 \times 10^6$  PFU of LCMV Cl 13,  $>80\%$  of  $DEC205<sup>+</sup>$  and  $CD11c<sup>+</sup>$  dendritic cells are infected (35),

| Groups inoculated with    | Infection of<br>$CD11c+$ and  | Immunosuppression of $\epsilon$ : |                | Incidence of | Day to clinical | Expression of TSE |
|---------------------------|-------------------------------|-----------------------------------|----------------|--------------|-----------------|-------------------|
| RML scrapie:              | $DEC205^+$ cells <sup>b</sup> | <b>CTL</b>                        | Antibody       | $TSE^d$      | disease         | disease in $CNSe$ |
| Orally                    |                               |                                   |                |              |                 |                   |
| Nonviral infection        | Nil                           | N <sub>0</sub>                    | N <sub>0</sub> | $4/4(100\%)$ | $d310 \pm 5$    | 3/3               |
| LCMV Cl 13 infection      | $+++ (>80\%)$                 | $++$                              | $++$           | $4/4(100\%)$ | $d305 \pm 5$    | 3/3               |
| <b>LCMV ARM</b> infection | $+$ ( $\leq 10\%$ )           | No                                | No             | $4/4(100\%)$ | $d310 \pm 5$    | 3/3               |
| 1.p.                      |                               |                                   |                |              |                 |                   |
| Nonviral infection        | Nil                           | No                                | No             | $6/6(100\%)$ | $d268 \pm 3$    | 3/3               |
| LCMV Cl 13 infection      | $+++ (>80\%)$                 | $++$                              | $++$           | 8/9(89%)     | $d272 \pm 4$    | 3/3               |
| <b>LCMV ARM</b> infection | $+$ ( $\leq 10\%$ )           | No                                | No             | $6/6(100\%)$ | $d269 \pm 3$    | 3/3               |

TABLE 2. Study of peripheral scrapie infection in mice with dysfunction of splenic DEC205<sup>+</sup> and CD11c<sup>+</sup> lymphoid dendritic cells<sup>*a*</sup>

<sup>*a*</sup> Six- to eight-week-old BALB mice were inoculated i.v. with  $2 \times 10^6$  PFU of LCMV Cl 13 or LCMV ARM. Twelve days later these mice and a control uninfected group were given 10<sup>7</sup> LD<sub>50</sub> of RML scrapie orally or i.p.

 $b$  Numbers of CD11c<sup>+</sup> cells and DEC205<sup>+</sup> cells following either LCMV Cl 13 or LCMV ARM infection were determined as reported using dual labeling with antibodies to CD11c<sup>+</sup> or DEC205<sup>+</sup> proteins for cell surface marker

Assays to detect immunosuppression of MHC-restricted CD8<sup>+</sup> cytotoxic T lymphocytes specific for LCMV, vaccinia virus, or herpes simplex virus at day 7 to 8 after infection or to detect antibodies to human immunoglobulin G or keyhole limpet hemocyanin at days 28, 45, 100, and 150 after inoculation. See references 7, 29, 35, and 37. ++, 10- to 30-fold decrease in immune response compared to control mice. *d* Number of mice with TSE/number studied.

<sup>e</sup> Number of mice developing histologic evidence of CNS TSE disease, i.e., expressing PrP<sup>sc</sup> or having infectious scrapie upon i.c. transfer to B6 mice/total number studied per group.

splenic architecture is disrupted (7, 21, 28, 35–37), replication occurs primarily in the splenic white pulp (7, 21, 35, 37), and a generalized immunosuppression lasting more than 6 months ensues (7, 35, 37) (unpublished data). By contrast, i.v. inoculation of  $2 \times 10^6$  PFU of the parental LCMV strain Armstrong (ARM) (which differs by two amino acids from the LCMV Cl 13 variant) (33), yields only minimal infection of  $DEC205<sup>+</sup>$  and  $CD11c<sup>+</sup>$  (<10%) cells (35), replicates preferentially in the red pulp of the spleen (21, 35, 36), causes only minimal disorganization of the splenic architecture early in infection, and does not cause immunosuppression (7, 35, 37).

At 12 days after LCMV Cl 13 inoculation, when more than  $80\%$  of DEC205<sup>+</sup> and CD11c<sup>+</sup> cells are infected, immunosuppression is extensive and these dendritic cells cannot act as antigen-presenting cells (7, 35), LCMV-infected mice were given  $10^7$  LD<sub>50</sub> of RML scrapie orally or i.p. As shown in Table 2 for both oral and i.p. administration of scrapie, mice with and without impairment of their  $DEC205^+$  or  $CD11c^+$  cells developed TSE disease at equivalent times and had PrPsc and infectious scrapie in their brains. Because the spleen is known to be an important site of amplification and accumulation of scrapie infectivity in mice, we tested spleens of  $LT-\alpha^{-/-}$  or  $LT-\beta$ <sup>-/-</sup> mice by Western blot analysis for PrP<sup>sc</sup> and found all to be negative (three of three mice tested per group at 60 and 200 days after scrapie inoculation) in contrast to wild-type control mice and mice coinfected with LCMV and scrapie (data not shown). Overall, these studies suggest that a peripheral cell other than FDCs and interdigitating dendritic cells  $(DEC205^+, CD11c^+),$  and presumably not located in the spleen, might be involved in the amplification of PrP<sup>sc</sup>.

**Peripheral scrapie infection in mice with genetic inactivation of other genes involved in the lymphoid system does not alter the kinetics for development of TSE.** We evaluated whether other lymphoid cells were involved in scrapie infection by using a panel of gene knockout mice. Equivalent patterns of scrapie infection were found in CD8, CD4,  $\beta$ 2 microglobulin, and MHC class II knockout mice and wild-type control mice after oral administration of scrapie. Similarly, after i.p. scrapie administration the initiation and incidence of TSE disease were virtually identical with those for wild-type controls in  $\beta$ 2 microglobulin and MHC class II knockout mice and, in agreement with the earlier report of Klein et al. (19), in  $CD8^{-/-}$  and  $CD4^{-/-}$  mice.

### **DISCUSSION**

Our study focused primarily on the oral transmission of scrapie to the CNS. Using a battery of gene knockout mice, we noted several intriguing findings. Notably,  $LT-\alpha^{-/-}$  mice devoid of FDCs undergo neuroinvasion and replication of infectious scrapie after oral inoculation. This neuroinvasion in LT-  $\alpha^{-/-}$  mice also occurs after i.p. inoculation. A profound difference in susceptibility to the development of TSE disease occurs in LT- $\alpha^{-/-}$  compared to LT- $\beta^{-/-}$  mice. The differences in kinetics and susceptibility of TSE disease between  $LT-\alpha$ <sup>-/-</sup> and  $LT-\beta^{-/-}$  mice, for both of which groups FDCs are deleted as observed by several investigators (2, 13, 14, 20) and reconfirmed here, suggest the likelihood that an additional, previously unidentified cell type may be important for replication of TSE infectivity. Last, neuroinvasion of scrapie occurred in mice in which the function of  $CD11c<sup>+</sup>$  cells was compromised.

Our results with  $LT-\beta^{-/-}$  mice inoculated with scrapie i.p. differ slightly from those of Manuelidis et al. (24), who studied i.p. inoculation of  $LT-\beta^{-/-}$  and  $LT-\beta^{+/+}$  mice. These investigators utilized a different source of infectious TSE material, mouse-adapted human Creutzfeldt-Jakob disease, strain Fukuoka-2. After inoculation of 2,000 infectious units, the disease incidence was 100% but a significant increase in the incubation period in  $LT-\beta^{-/-}$  mice was observed, whereas after 20 infectious units the incidence of disease was lower in  $LT-\beta^{-/-}$  mice. In contrast, we used a very high dose of the RML strain of mouse scrapie and found a disease incidence of only 5 out of 16 after i.p. infection of  $LT-\beta^{-/-}$  mice. The differences in incidence of disease observed with  $LT-\beta^{-/-}$  mice in these experiments may be related to the TSE strains used. For example, the Fukuoka-2 strain may be less dependent on

replication in FDCs prior to neuroinvasion than is the RML strain.

Earlier studies detected  $PrP^{sc}$  in FDCs from spleens  $(8, 9, 1)$ 17, 23, 25–27). However, in our experiments the differences between  $LT$ - $\alpha$ <sup>-/-</sup> and  $LT$ - $\beta$ <sup>-/-</sup> mice, for both of which FDCs are deleted, suggest that an additional, previously unidentified cell type is also likely important for replication of TSE infectivity. However, we cannot exclude, although unlikely, the possibility of a small subset of FDCs in  $LT-\alpha^{-/-}$  mice that is not recognized by FDC-M2 antibodies and the possibility that this subset of FDCs is missing in  $LT-\beta^{-/-}$  mice. Recently, Aucouturier et al.  $(3)$ , using adoptive transfers, reported that CD11 $c^+$ splenic dendritic cells from scrapie-infected mice were able to transmit TSE. Our experiments with LCMV Cl 13 and our inability to find PrP<sup>sc</sup> in spleens of LT- $\alpha^{-/-}$  or LT- $\beta^{-/-}$  mice indicate that a cell in addition to  $DEC205<sup>+</sup>$  or  $CD11c<sup>+</sup>$  dendritic cells is likely involved. Further, comparing a panel of gene knockout mice suggests that CD4 or CD8 T cells or cells bearing MHC class II molecules are not likely the source of PrPsc amplification. These results are further supported by our lymphoid cell transfer from LT- $\beta$ <sup>-/-</sup> mice into LT- $\alpha$ <sup>-/-</sup> mice, which failed to alter the kinetics of TSE infection of  $LT-\alpha^{-/-}$ mice. Use of high doses of hamster scrapie administered orally or i.p. into mice in which hamster PrP expression was restricted to neurons using the neuron-specific enolase promoter (31, 32) showed that neuroinvasion can occur in the absence of PrP expression in FDCs or  $CD11c<sup>+</sup>$  cells. While passage of scrapie infection from the peripheral site to the CNS occurs via neuronal transport, FDCs (see review  $(40)$  and perhaps CD11 $c^+$ dendritic cells play an important role in the amplification of infectivity prior to neuroinvasion, our data here coupled with an earlier report by Klein et al. (19) using TNF receptor  $1^{-/-}$ mice devoid of FDCs suggest that an additional, yet-to-bedefined cell in the periphery can also replicate and amplify scrapie infectivity. Further,  $LT$ - $\alpha$ <sup>-/-</sup> and  $LT$ - $\beta$ <sup>-/-</sup> mice handle the RML scrapie agent in distinctive ways, suggesting that these models may be informative for the search of the unknown cell(s). Interestingly and in contrast to these studies with scrapie,  $LT$ - $\alpha$ <sup>-/-</sup> mice and  $LT$ - $\beta$ <sup>-/-</sup> mice have been reported to handle another infectious agent equivalently (6).

#### **ACKNOWLEDGMENTS**

The work was supported, in part, by U.S. Public Health Service grant AG04342.

We thank Antoinette Tishon, Chao P. Teng, and Noemi Sevilla for technical assistance; Matthias von Herrath for assistance with the transplantation surgery; Y.-X. Fu for helpful discussions; M. Kosco-Vilbois for the FDC-M2 antibody; and Michael Grusby for the MHC class  $II^{-/-}$  mice.

## **ADDENDUM IN PROOF**

Concurrent with this article's acceptance, Prinz et al. published similar results (M. Prinz, F. Montrasio, M. A. Klein, P. Schwarz, J. Priller, B. Odermatt, K. Pfeffer, and A. Aguzzi, Proc. Natl. Acad. Sci. USA **99:**919–924, 2002).

#### **REFERENCES**

1. **Ahmed, R., A. Salmi, L. D. Butler, J. M. Chiller, and M. B. A. Oldstone.** 1984. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice: role in suppression of cytotoxic T lymphocyte response and viral persistence J. Exp. Med. **160:**521–540.

- 2. **Alimzhanov, M. B., D. V. Kuprash, M. H. Kosco-Vilbois, A. Luz, R. L. Turetskaya, A. Tarakhovsky, K. Rajewsky, S. A. Nedospasov, and K. Pfeffer.** 1997. Abnormal development of secondary lymphoid tissues in lymphotoxin beta-deficient mice. Proc. Natl. Acad. Sci. USA **94:**9302–9307.
- 3. **Aucouturier, P., F. Geissmann, D. Damotte, G. P. Saborio, H. C. Meeker, R. Kascsak, R. Kascsak, R. I. Carp, and T. Wisniewski.** 2001. Infected splenic dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie. J. Clin. Investig. **108:**703–708.
- 4. **Banks, T. A., B. T. Rouse, M. K. Kerley, P. J. Blair, V. L. Godfrey, N. A. Kuklin, D. M. Bouley, J. Thomas, S. Kanangat, and M. L. Mucenski.** 1995. Lymphotoxin-alpha-deficient mice. Effects on secondary lymphoid organ development and humoral immune responsiveness. J. Immunol. **15:**1685– 1693.
- 5. **Beekes, M., P. A. McBride, and E. Baldauf.** 1998. Cerebral targeting indicates vagal spread of infection in hamsters fed with scrapie. J. Gen. Virol. **79:**601–607.
- 6. **Berger, D. P., D. Naniche, M. T. Crowley, P. A. Koni, R. A. Flavell, and M. B. A. Oldstone.** 1999. Lymphotoxin beta deficient mice show defective antiviral immunity. Virology **260:**136–147.
- 7. **Borrow, P., C. F. Evans, and M. B. A. Oldstone.** 1995. Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression J. Virol. **69:**1059–1070.
- 8. **Brown, K. L., K. Stewart, D. L. Ritchie, N. A. Mabbott, A. Williams, H. Fraser, W. I. Morrison, and M. E. Bruce.** 1999. Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells. Nat. Med. **5:**1308–1312.
- 9. **Bruce, M. E., K. L. Brown, N. A. Mabbott, C. F. Farquhar, and M. Jeffrey.** 2000. Follicular dendritic cells in TSE pathogenesis. Immunol. Today **21:** 442–446.
- 10. **Burkly, L., C. Hession, L. Ogata, C. Reilly, L. A. Marconi, D. Olson, R. Tizard, R. Cate, and D. Lo.** 1995. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature **373:**531–536.
- 11. **Campbell, I. L., M. Eddleston, P. Kemper, M. B. A. Oldstone, and M. V. Hobbs.** 1994. Activation of cerebral cytokine gene expression and its correlation with onset of molecular pathology in scrapie. J. Virol. **68:**2383–2387.
- 12. **Chesebro, B.** 1999. Prion protein and the transmissible spongiform encephalopathy diseases. Neuron **24:**503–506.
- 13. **De Togni, P., J. Goellner, N. H. Ruddle, P. R. Streeter, A. Fick, S. Mariathasan, S. C. Smith, R. Carlson, L. P. Shornick, and J. Strauss-Schoenberger.** 1994. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science **264:**703–707.
- 14. **Fu, Y.-X., G. Huang, M. Matsumoto, H. Molina, and D. D. Chaplin.** 1997. Independent signals regulate development of primary and secondary follicle structure in spleen and mesenteric lymph node. Proc. Natl. Acad. Sci. USA **94:**5739–5743.
- 15. **Futterer, A., K. Mink, A. Luz, M. H. Kosco-Vilbois, and K. Pfeffer.** 1998. The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity **9:**59–70.
- 16. **Holz, A., A. Bot, B. Coon, T. Wolfe, M. J. Grusby, and M. G. von Herrath.** 1999. Disruption of the STAT4 signaling pathway protects from autoimmune diabetes while retaining antiviral immune competence. J. Immunol. **163:** 5374–5382.
- 17. **Jeffrey, M., G. McGovern, C. M. Goodsir, K. L. Brown, and M. E. Bruce.** 2000. Sites of prion protein accumulation in scrapie-infected mouse by immuno-electron microscopy. J. Pathol. **191:**323–332.
- 18. **Kimberlin, R. H., and C. A. Walker.** 1980. Pathogenesis of mouse scrapie: evidence for neural spread of infection to the CNS. J. Gen. Virol. **51:**183– 187.
- 19. **Klein, M. A., R. Frigg, E. Flechsig, A. J. Raeber, U. Kalinke, H. Bluethmann, F. Bootz, M. Suter, R. M. Zinkernagel, and A. Aguzzi.** 1997. A crucial role for B cells in neuroinvasive scrapie. Nature **390:**687–690.
- 20. **Koni, P. A., R. Sacca, P. Lawton, J. L. Browning, N. H. Ruddle, and R. A. Flavell.** 1997. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity **6:**491–500.
- 21. **Kunz, S., N. Sevilla, D. McGavern, K. P. Campbell, and M. B. A. Oldstone.** 2001. Molecular analysis of the interaction of LCMV with its cellular receptor alpha-dystroglycan. J. Cell Biol. **155:**301–310.
- 22. Liu,  $\dot{Y}$ .-J., and J. Banchereau. 1996. Mutant mice without B lymphocyte follicles. J. Exp. Med. **184:**1207–1211.
- 23. **Mabbott, N. A., F. Mackay, F. Minns, and M. E. Bruce.** 2000. Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie. Nat. Med. **6:**719–720.
- 24. **Manuelidis, L., I. Zaitsev, P. A. Koni, Z. Y. Lu, R. A. Flavell, and W. Fritch.** 2000. Follicular dendritic cells and dissemination of Creutzfeldt-Jakob disease. J. Virol. **74:**8614–8622.
- 25. **McBride, P. A., P. Eikelenboom, G. Kraal, H. Fraser, and M. E. Bruce.** 1992. PrP protein is associated with follicular dendritic cells of spleens and lymph nodes in uninfected and scrapie-infected mice. J. Pathol. **168:**413–418.
- 26. **Montrasio, F., A. Cozzio, E. Flechsig, D. Rossi, M. A. Klein, T. Rulicke, A. J. Raeber, C. A. J. Vosshenrich, J. Proft, A. Aguzzi, and C. Weissmann.** 2001.

B-lymphocyte-restricted expression of prion protein does not enable prion replication in PrP knockout mice. Proc. Natl. Acad. Sci. USA **98:**4034–4037.

- 27. **Montrasio, F., R. Frigg, M. Glatzel, M. A. Klein, F. Mackay, A. Aguzzi, and C. Weissmann.** 2000. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science **288:**1257–1259.
- 28. **Odermatt, B., M. Eppler, T. P. Leist, H. Hengartner, and R. M. Zinkernagel.** 1991. Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure. Proc. Natl. Acad. Sci. USA **88:**8252–8256.
- 29. **Oldstone, M. B. A., A. Tishon, J. Chiller, W. Weigle, and F. J. Dixon.** 1973. Effect of chronic viral infection on the immune system. I. Comparison of the immune responsiveness of mice chronically infected with LCM virus with that of noninfected mice. J. Immunol. **110:**1268–1278.
- 30. **Prusiner, S. B.** 2001. Prions, p. 3063–3087. *In* D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, Pa.
- 31. **Race, R., M. Oldstone, and B. Chesebro.** 2000. Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: role of prion protein expression in peripheral nerves and spleen. J. Virol. **74:**828– 833.
- 32. **Race, R. E., S. A. Priola, R. A. Bessen, D. Ernst, J. Dockter, G. F. Rall, L. Mucke, B. Chesebro, and M. B. A. Oldstone.** 1995. Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron **15:**1183–1191.
- 33. **Salvato, M., E. Shimomaye, P. Southern, and M. B. A. Oldstone.** 1988. Virus-lymphocyte interactions. IV. Molecular characterization of LCMV

Armstrong (CTL+) and that of its variant, Clone 13 (CTL-). Virology **164:**517–522.

- 34. **Scott, J. R., D. Davies, and H. Fraser.** 1992. Scrapie in the central nervous system: neuroanatomical spread of infection and Sinc control of pathogenesis. J. Gen. Virol. **73:**1637–1644.
- 35. **Sevilla, N., S. Kunz, A. Holz, H. Lewicki, D. Homann, H. Yamada, K. P. Campbell, J. C. de la Torre, and M. B. A. Oldstone.** 2000. Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J. Exp. Med. **192:**1249–1260.
- 36. **Smelt, S. C., P. Borrow, S. Kunz, W. Cao, A. Tishon, H. Lewicki, K. P. Campbell, and M. B. A. Oldstone.** 2000. Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor alphadystroglycan correlate with viral tropism and disease kinetics. J. Virol. **75:** 448–457.
- 37. **Tishon, A., P. Borrow, C. F. Evans, and M. B. A. Oldstone.** 1993. Virusinduced immunosuppression. I. Age at infection relates to a selective or generalized defect. Virology **195:**397–405.
- 38. **von Herrath, M. G., J. Dockter, M. Nerenberg, J. E. Gairin, and M. B. A. Oldstone.** 1994. Thymic selection and adaptability of cytotoxic T lymphocyte responses in transgenic mice expressing a viral protein in the thymus. J. Exp. Med. **180:**1901–1910.
- 39. **Ware, C. F., T. L. VanArsdale, P. D. Crowe, and J. L. Browning.** 1995. The ligands and receptors of the lymphotoxin system. Curr. Top. Microbiol. Immunol. **198:**175–218.
- 40. **Weissmann, C., A. J. Raeber, F. Montrasio, I. Hegyi, R. Frigg, M. A. Klein, and A. Aguzzi.** 2001. Prions and the lymphoreticular system. Philos. Trans. R. Soc. Lond. B. Biol. Sci. **356:**177–184.